Contribute Try STAT+ Today

A former senior executive at Taro Pharmaceuticals USA was indicted for his role in a wide-ranging conspiracy to fix prices for generic drugs, the third time that a high-ranking drug company official has been charged since federal authorities began their investigation several years ago.

Ara Aprahamian, a former vice president of sales and marketing at the company, was indicted for working with executives at another drug maker to increase prices and allocate customers for numerous drugs, including medicines used to treat and manage arthritis, seizures, pain, various skin conditions, and blood clots, according to the indictment that was filed in federal court in Philadelphia.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Ah. I must observe that this event was certainly ‘in the cards.’ Now one must wonder, has the full hand been dealt or not?

Comments are closed.